filgrastim sold brand name neupogen among others medication used treat low neutrophil low neutrophil counts may occur hivaids following chemotherapy radiation poisoning unknown may also used increase white blood cells gathering given either injection vein filgrastim leukocyte growth common side effects include fever cough chest pain joint pain vomiting hair severe side effects include splenic rupture allergic unclear use pregnancy safe filgrastim recombinant form naturally occurring granulocyte colonystimulating factor works stimulating body increase neutrophil filgrastim approved medical use united states world health organizations list essential filgrastim biosimilar medications filgrastim used treat acute myeloid nonmyeloid congenital cyclic idiopathic myelosuppressive doses tbofilgrastim granix indicated reduction duration severe neutropenia people nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated clinically significant incidence febrile commonly observed adverse effect mild bone pain repeated local skin reactions site observed adverse effects include serious allergic reactions including rash whole shortness breath wheezing dizziness swelling around mouth eyes fast pulse sweating ruptured spleen sometimes resulting alveolar hemorrhage acute respiratory distress syndrome severe sickle cell crises cases resulting death associated use filgrastim people sickle cell increased hematopoietic activity bone marrow response growth factor therapy associated transient positive bone imaging changes considered interpreting boneimaging gcsf colony stimulating factor shown minimal direct vivo vitro effects production haematopoietic cell types neupogen filgrastim name recombinant methionyl human granulocyte colony stimulating factor sandozs filgrastimsndz trade name zarxio obtained approval us food drug administration fda first product passed biologics price competition innovation act bpci act part affordable care zarxio approved biosimilar interchangeable product fda notes bpci act biologic approved interchangeable may substituted reference product without intervention health care provider prescribed reference product fda said approval zarxio based review evidence included structural functional characterization animal study data human pharmacokinetic pharmacodynamics data clinical immunogenicity data clinical safety effectiveness data demonstrates zarxio biosimilar filgrastimaafi trade name nivestym approved use united september ratiograstim tevagrastim biograstim filgrastim ratiopharm approved use european filgrastim ratiopharm withdrawn july biograstim withdrawn december february filgrastim hexal zarzio approved use european june nivestim approved use european october grastofil approved use european september accofil approved use european fraven approved use republic turkey ministry nivestym approved medical use canada april october nypozi approved medical use shortly introduced analyses whether filgrastim costeffective way preventing febrile neutropenia depended upon clinical situation financial model used pay longeracting pegfilgrastim may cases httpsenwikipediaorgwikifilgrastim